Vir Biotechnology, Inc. Profile Avatar - Palmy Investing

Vir Biotechnology, Inc.

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection unde…
Biotechnology
US, San Francisco [HQ]
VIR/Leadership and Strategy

Risk Factors

By Management
Not Available

    No Risk Factor available yet. You can request "Risk Factors" through an email.

End of VIR's Analysis
CIK: 1706431 CUSIP: 92764N102 ISIN: US92764N1028 LEI: - UEI: -
Secondary Listings
VIR has no secondary listings inside our databases.